FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2567686598> ?p ?o ?g. }

• W2567686598 endingPage "309" @default.
• W2567686598 startingPage "303" @default.
• W2567686598 abstract "Background Pemetrexed and bevacizumab as single agents have been approved for maintenance therapy after platinum-based induction in patients with advanced nonsquamous non–small-cell lung cancer. It is currently unknown whether bevacizumab plus pemetrexed is superior to pemetrexed alone. Patients and Methods We conducted a nonrandomized phase II trial with 2 sequential cohorts. In the first cohort, 77 patients were treated with 4 cycles of cisplatin, bevacizumab, and pemetrexed every 3 weeks, followed by bevacizumab plus pemetrexed maintenance until progression. In the second cohort, we treated 52 patients without bevacizumab, using maintenance with pemetrexed alone. Progression-free survival (PFS), overall survival (OS), overall response rate (ORR), adverse events, and the treatment costs of the 2 cohorts were compared. Results The median PFS from the time of registration was 6.9 months in cohort 1 and 5.6 months in cohort 2. The ORR was 62.3% in cohort 1% and 44.2% in cohort 2. The PFS (hazard ratio, 0.7; 95% confidence interval [CI], 0.5-1.0; P = .041) and ORR (odds ratio, 2.1; 95% CI, 1.0-4.3; P = .049) were better in cohort 1 than in cohort 2. No OS difference was found (hazard ratio, 1.0; 95% CI, 0.7-1.6; P = .890) after a median follow-up period of 47 months for cohort 1 and 27 months for cohort 2. The rate of grade ≥ 3 adverse events was greater in cohort 1. The treatment costs per patient were on average 1.4 times greater for cohort 1. Conclusion The addition of bevacizumab increased the ORR and PFS, but not OS, in our nonrandomized trial. Furthermore, the addition of bevacizumab was associated with greater toxicity and higher costs." @default.
• W2567686598 created "2017-01-06" @default.
• W2567686598 creator A5001536238 @default.
• W2567686598 creator A5007155024 @default.
• W2567686598 creator A5008022418 @default.
• W2567686598 creator A5011868198 @default.
• W2567686598 creator A5012411744 @default.
• W2567686598 creator A5020235177 @default.
• W2567686598 creator A5020563845 @default.
• W2567686598 creator A5034361476 @default.
• W2567686598 creator A5038016963 @default.
• W2567686598 creator A5044032162 @default.
• W2567686598 creator A5050931392 @default.
• W2567686598 creator A5063300526 @default.
• W2567686598 creator A5066701721 @default.
• W2567686598 creator A5068350308 @default.
• W2567686598 creator A5070375776 @default.
• W2567686598 creator A5080098952 @default.
• W2567686598 creator A5086220270 @default.
• W2567686598 creator A5091137864 @default.
• W2567686598 date "2017-05-01" @default.
• W2567686598 modified "2023-09-24" @default.
• W2567686598 title "Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non–Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial" @default.
• W2567686598 cites W2005244154 @default.
• W2567686598 cites W2010993494 @default.
• W2567686598 cites W2037139573 @default.
• W2567686598 cites W2040253672 @default.
• W2567686598 cites W2096216990 @default.
• W2567686598 cites W2099725888 @default.
• W2567686598 cites W2112621029 @default.
• W2567686598 cites W2115330744 @default.
• W2567686598 cites W2122798232 @default.
• W2567686598 cites W2125665528 @default.
• W2567686598 cites W2128002599 @default.
• W2567686598 cites W2136023414 @default.
• W2567686598 cites W2141197908 @default.
• W2567686598 cites W2145835533 @default.
• W2567686598 cites W2146074984 @default.
• W2567686598 cites W2148367564 @default.
• W2567686598 cites W2156438240 @default.
• W2567686598 cites W2170552969 @default.
• W2567686598 cites W2239287815 @default.
• W2567686598 cites W4238604577 @default.
• W2567686598 doi "https://doi.org/10.1016/j.cllc.2016.11.007" @default.
• W2567686598 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27993482" @default.
• W2567686598 hasPublicationYear "2017" @default.
• W2567686598 type Work @default.
• W2567686598 sameAs 2567686598 @default.
• W2567686598 citedByCount "10" @default.
• W2567686598 countsByYear W25676865982018 @default.
• W2567686598 countsByYear W25676865982019 @default.
• W2567686598 countsByYear W25676865982020 @default.
• W2567686598 countsByYear W25676865982021 @default.
• W2567686598 crossrefType "journal-article" @default.
• W2567686598 hasAuthorship W2567686598A5001536238 @default.
• W2567686598 hasAuthorship W2567686598A5007155024 @default.
• W2567686598 hasAuthorship W2567686598A5008022418 @default.
• W2567686598 hasAuthorship W2567686598A5011868198 @default.
• W2567686598 hasAuthorship W2567686598A5012411744 @default.
• W2567686598 hasAuthorship W2567686598A5020235177 @default.
• W2567686598 hasAuthorship W2567686598A5020563845 @default.
• W2567686598 hasAuthorship W2567686598A5034361476 @default.
• W2567686598 hasAuthorship W2567686598A5038016963 @default.
• W2567686598 hasAuthorship W2567686598A5044032162 @default.
• W2567686598 hasAuthorship W2567686598A5050931392 @default.
• W2567686598 hasAuthorship W2567686598A5063300526 @default.
• W2567686598 hasAuthorship W2567686598A5066701721 @default.
• W2567686598 hasAuthorship W2567686598A5068350308 @default.
• W2567686598 hasAuthorship W2567686598A5070375776 @default.
• W2567686598 hasAuthorship W2567686598A5080098952 @default.
• W2567686598 hasAuthorship W2567686598A5086220270 @default.
• W2567686598 hasAuthorship W2567686598A5091137864 @default.
• W2567686598 hasConcept C126322002 @default.
• W2567686598 hasConcept C141071460 @default.
• W2567686598 hasConcept C143998085 @default.
• W2567686598 hasConcept C197934379 @default.
• W2567686598 hasConcept C207103383 @default.
• W2567686598 hasConcept C2776256026 @default.
• W2567686598 hasConcept C2776694085 @default.
• W2567686598 hasConcept C2777240266 @default.
• W2567686598 hasConcept C2777802072 @default.
• W2567686598 hasConcept C2778239845 @default.
• W2567686598 hasConcept C44249647 @default.
• W2567686598 hasConcept C71924100 @default.
• W2567686598 hasConcept C72563966 @default.
• W2567686598 hasConceptScore W2567686598C126322002 @default.
• W2567686598 hasConceptScore W2567686598C141071460 @default.
• W2567686598 hasConceptScore W2567686598C143998085 @default.
• W2567686598 hasConceptScore W2567686598C197934379 @default.
• W2567686598 hasConceptScore W2567686598C207103383 @default.
• W2567686598 hasConceptScore W2567686598C2776256026 @default.
• W2567686598 hasConceptScore W2567686598C2776694085 @default.
• W2567686598 hasConceptScore W2567686598C2777240266 @default.
• W2567686598 hasConceptScore W2567686598C2777802072 @default.
• W2567686598 hasConceptScore W2567686598C2778239845 @default.
• W2567686598 hasConceptScore W2567686598C44249647 @default.
• W2567686598 hasConceptScore W2567686598C71924100 @default.
• W2567686598 hasConceptScore W2567686598C72563966 @default.

• next